Clinical trial
Evaluation of the efficacy of Tolcapone as a genotype-based targeted cognitive enhancer in Schizophrenia, based on the polymorphism rs4680
To assess the efficacy of tolcapone, as the first non-stimulant drug to improve cognition in schizophrenia, as a genotype-based targeted treatment of cognitive and negative symptoms of schizophrenia considering the polymorphism rs4680.
| Category | Value |
|---|---|
| Study start date | 2014-04-04 |